In patients with RA, TNF inhibitor use during the 3 years after being diagnosed with early-stage lung, colorectal, or prostate cancer was not linked to decreased survival.

The following is a summary of “Advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung ...

Rigel, of South San Francisco, California, is positioning R788 (tamatinib fodium), an inhibitor of Syk kinase, as a direct challenger to the tumor necrosis factor-alpha (TNF-α) inhibitor biologics.

TNF inhibitor use demonstrates no negative impact on survival among patients recently diagnosed with colorectal, lung or ...

which promotes the release of soluble TNF from its membrane-bound precursor. Inhibitors of this enzyme with drug-like properties have been made and tested in the clinic. These inhibitors include ...

BALTIMORE, February 25, 2025--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed ...

Granuloma annulare is a benign ... and tumor necrosis factor (TNF) inhibitors. The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has been implicated in ...

Isomyosamine is an oral, next-generation TNF-a inhibitor with the potential to transform the way TNF-a based diseases are treated due to its selectivity and ability to cross the blood brain barrier.

Isomyosamine is an oral, next-generation TNF-α inhibitor with the potential to transform the way TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier.

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory ...